GSK will acquire 35Pharma for $950 million.

LootboxPhobia · 2026-02-25T12:17:08+00:00

GSK agrees to acquire Canadian biopharmaceutical company 35Pharma for $950 million, aiming to strengthen its presence in cardiovascular and pulmonary therapies and obesity treatments. This deal reflects CEO Luke Miels' strategy to enhance drug R&D, with 35Pharma's lead candidate HS235 in early development.

LootboxPhobia

2026-02-25 12:17:08

Abstract generation in progress

Investing.com – GSK announced on Wednesday that it has agreed to acquire 35Pharma, based in Canada, for $950 million.

This deal will add cardiovascular and respiratory drugs to the British pharmaceutical company’s product portfolio and expand its presence in the field of obesity-related diseases.

The acquisition marks the latest move under GSK CEO Luke Miels, who has been focused on strengthening the company’s drug development pipeline since taking office.

35Pharma is a biopharmaceutical company focused on developing cardiovascular and respiratory therapies. Its lead candidate, HS235, is in early development for the treatment of various types of pulmonary hypertension.

Both companies stated that the drug’s mechanism of action also shows potential metabolic benefits, including fat reduction.

As GSK seeks to expand its product offerings in the treatment of obesity-related diseases, this deal further boosts the company’s recent acquisition activities.

This article was translated with the assistance of artificial intelligence. For more information, please see our Terms of Use.

View Original

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.